GenCore version 5.1.3

OM protein - protein search, using sw model

Run on: January 16, 2003, 16:34:37 ; Search time 23.7857 Seconds
(without alignments)
28.011 Million cell updates/sec

Title: US-09-856-070-16
Perfect score: 25
Sequence: 1 EREKE 5

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_101002 *
1: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	25	100.0	5	22	AAB82034	Human hepreceptor
2	25	100.0	8	23	AAM49728	Octapeptide used i
3	25	100.0	9	22	AAB82033	Human hepreceptor
4	25	100.0	9	23	AAM49724	Nonapeptide used i
5	25	100.0	11	22	AAB82031	Human hepreceptor
6	25	100.0	12	18	AAW26551	Epithelial protein
7	25	100.0	12	19	AAW50920	Amino acid sequenc
8	25	100.0	12	22	AAB82028	Human hepreceptor
9	25	100.0	14	17	AAR88086	Human endogenous p
10	25	100.0	14	22	AAB82035	Human hepreceptor
11	25	100.0	14	22	AAB82046	Human hepreceptor
12	25	100.0	14	23	AAM49722	HEF-1 associated p
13	25	100.0	32	22	AAB82019	Human hepreceptor
14	25	100.0	34	22	AAO08880	Human polypeptide
15	25	100.0	39	22	ABB30745	Peptide #3396 enco
16	25	100.0	39	22	ABB35922	Peptide #3428 enco
17	25	100.0	39	22	ABB21331	Protein #3330 enco
18	25	100.0	39	22	AAM56725	Human brain expres
19	25	100.0	39	22	AAM69103	Human bone marrow
20	25	100.0	39	22	AAM16939	Peptide #3373 enco
21	25	100.0	39	22	AAM29424	Peptide #3461 enco
22	25	100.0	39	22	AAM04632	Peptide #3314 enco
23	25	100.0	39	23	ABG38700	Human peptide enco
24	25	100.0	43	21	AAB34541	Human secreted pro
25	25	100.0	46	22	ABB30605	Peptide #3256 enco
26	25	100.0	46	22	ABB35769	Peptide #3275 enco
27	25	100.0	46	22	ABB21193	Protein #3192 enco
28	25	100.0	46	22	AAM56579	Human brain expres
29	25	100.0	46	22	AAM68959	Human bone marrow
30	25	100.0	46	22	AAM16785	Peptide #3219 enco
31	25	100.0	46	22	AAM29270	Peptide #3307 enco
32	25	100.0	46	22	AAM04502	Peptide #3184 enco
33	25	100.0	46	23	ABG38545	Human peptide enco
34	25	100.0	46	23	ABP29506	Streptococcus poly
35	25	100.0	51	22	AAO10368	Human polypeptide
36	25	100.0	55	22	ABB39078	Peptide #5784 enco
37	25	100.0	55	22	ABB23998	Protein #5997 enco
38	25	100.0	55	22	AAM59730	Human brain expres
39	25	100.0	55	22	AAM72312	Human bone marrow
40	25	100.0	55	22	AAM32571	Peptide #5698 enco
41	25	100.0	55	23	ABG42127	Human peptide enco
42	25	100.0	57	22	ABB41635	Peptide #8541 enco
43	25	100.0	57	22	AAM61890	Human brain expres
44	25	100.0	57	22	AAM74692	Human bone marrow
45	25	100.0	57	22	AAO12962	Human polypeptide

ALIGNMENTS

RESULT 1
AAB82034
ID AAB82034 standard; peptide; 5 AA.
XX
AC AAB82034;
XX
DT 13-JUN-2001 (first entry)
XX
DE Human hepreceptor domain B binding peptide Rupe1014.
XX
KW Human hepreceptor; cytostatic; anti-HIV; antibiotic;
KW neurotropic; immune response inducer; ezrin; infectious diseases; cancer;
KW HIV-related dementia.
XX
OS Homo sapiens.
XX
PN GB2354241-A.
XX
PD 21-MAR-2001.
XX
PF 17-SEP-1999; 99GB-0021881.
XX
PR 17-SEP-1999; 99GB-0021881.
XX
PA (HOLM/) HOLMS R D.
XX
PI Holms RD;
XX
DR WPI; 2001-293287/31.
XX
PT Novel regulator, or unfolding peptides of ezrin that binds to
PT Hepreceptor, useful for inducing immune response for treating
PT infectious diseases and cancer -

XX
PS Claim 19; Page 36; 42pp; English.
XX
CC The hepreceptor is a novel active site in human ezrin. Ezrin regulates
CC the structure of the cortical cytoskeleton to control cell surface
CC topography. The present invention relates to peptides (see AAB82021 to
CC AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see
CC AAB82046). The hepreceptor binding peptides are useful for inducing
CC immune response, and for treating infectious diseases, cancer and
CC HIV-related dementia. The present peptide binds to domain B of the
CC hepreceptor (AAB82020).
XX
SQ Sequence 5 AA;

Query Match 100.0%; Score 25; DB 22; Length 5;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EREKE 5
||||| |
Db 1 EREKE 5

RESULT 2
AAM49728
ID AAM49728 standard; peptide; 8 AA.
XX
AC AAM49728;
XX
DT 14-JUN-2002 (first entry)
XX
DE Octapeptide used in peptide synthesis.
XX
KW Tetradecapeptide synthesis; condensation; protein chemistry,
KW biochemistry.
XX
OS Unidentified.
XX
FH Key Location/Qualifiers
FT Modified site 1
FT /label= OTHER
FT /note= "Glu(But), optionally Z-Glu(But)"
FT Modified-site 2
FT /label= OTHER
FT /note= "Thr(But)"
FT Modified site 4
FT /label= OTHER
FT /note= "Glu(But)"
FT Modified-site 6
FT /label= OTHER
FT /note= "Glu(But)"
FT Modified-site 7
FT /label= OTHER
FT /note= "Lys(Boc)"
FT Modified site 8
FT /label= OTHER
FT /note= "Glu(But)-OBut"
XX
PN RU2175973-C1.
XX
PD 20-NOV-2001.
XX
PF 10-AUG-2000; 2000RU-0120792
XX
PR 10-AUG-2000; 2000RU-0120792.
XX
PA (GEPV-) GEPVITANIYA LTD.
XX
PI Pomogaibo SV, Buryakova AA;
XX
DR WPI; 2002-081347/11.
XX
PT Method of synthesis of tetradecapeptide

XX
PS Disclosure; Column 4; 6pp; Russian.
XX
CC This invention describes a novel method for the synthesis of
CC tetradecapeptides of the general formula
CC H-Thr-Glu-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg Glu Lys-Glu-OH. The method
CC involves condensation of a pentapeptide of the formula:
CC Z-Thr(But)-Glu(But)-Lys(Boc)-Lys(Boc)-Arg-OH with nonapeptide of the
CC formula: Arg-Glu(But)-Thr(But)-VAl-Glu(But)-Arg-Glu(But)-Lys(Boc)-Glu
CC (But) OBut followed by removal of protective groups in the synthesized
CC semiproduct and preparing the end product. The method of the invention
CC has applications for protein chemistry and biochemistry. This sequence
CC represents a peptide used to illustrate the method of the invention.
XX
SQ Sequence 8 AA;

Query Match 100.0%; Score 25; DB 23; Length 8;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EREKE 5
||||| |
Db 4 EREKE 8

RESULT 3
AAB82033
ID AAB82033 standard; peptide; 9 AA.
XX
AC AAB82033;
XX
DT 13-JUN-2001 (first entry)
XX
DE Human hepreceptor domain B binding peptide Rupep14.
XX
KW Human; hepreceptor; cytostatic; anti-HIV; antibiotic;
KW nootropic; immune response inducer; ezrin; infectious diseases; cancer;
KW HIV-related dementia.
XX
OS Homo sapiens.
XX
PN GB2354241-A.
XX
PD 21-MAR-2001.
XX
PF 17-SEP-1999; 99GB-0021881.
XX
PR 17-SEP-1999; 99GB-0021881.
XX
PA (HOLM/) HOLMS R D.
XX
PI Holms RD;
XX
DR WPI; 2001-293287/31.
XX
PT Novel regulatory or unfolding peptides of ezrin that binds to
PT Hepreceptor, useful for inducing immune response for treating
PT infectious diseases and cancer -
XX
PS Claim 18; Page 36; 42pp; English.
XX
CC The hepreceptor is a novel active site in human ezrin. Ezrin regulates
CC the structure of the cortical cytoskeleton to control cell surface
CC topography. The present invention relates to peptides (see AAB82021 to
CC AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see
CC AAB82046). The hepreceptor binding peptides are useful for inducing
CC immune response, and for treating infectious diseases, cancer and
CC HIV-related dementia. The present peptide binds to domain B of the
CC hepreceptor (AAB82020).
XX
SQ Sequence 9 AA;

Query Match 100.0%; Score 25; DB 22; Length 9;

```
  Best Local Similarity   100.0%;  Pred. No. 7.8e+05;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0,  Gaps    0,

Qy       1 EREKE 5
           |||||
Db       5 EREKE 9


RESULT 4
AAM49724
ID   AAM49724 standard; peptide; 9 AA.
XX
AC   AAM49724;
XX
DT   14-JUN-2002  (first entry)
XX
DE   Nonapeptide used in peptide synthesis.
XX
KW   Tetradecapeptide synthesis, condensation, protein chemistry,
KW   biochemistry.
XX
OS   Unidentified.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   2
FT                   /label= OTHER
FT                   /note= "Glu(But)"
FT   Modified-site   3
FT                   /label= OTHER
FT                   /note= "Thr(But)"
FT   Modified-site   5
FT                   /label= OTHER
FT                   /note= "Glu(But)"
FT   Modified-site   7
FT                   /label= OTHER
FT                   /note= "Glu(But)"
FT   Modified-site   8
FT                   /label= OTHER
FT                   /note= "Lys(Boc)"
FT   Modified-site   9
FT                   /label= OTHER
FT                   /note= "Glu(But)-OBut"
XX
PN   RU2175973-C1.
XX
PD   20-NOV-2001.
XX
PF   10-AUG-2000; 2000RU-0120792.
XX
PR   10-AUG-2000; 2000RU-0120792.
XX
PA   (GEPV-) GEPVITANIYA LTD.
XX
PI   Pomogaibo SV,  Buryakova AA;
XX
DR   WPI; 2002-081347/11.
XX
PT   Method of synthesis of tetradecapeptide  -
XX
PS   Claim 1; Column 3; 6pp; Russian.
XX
CC   This invention describes a novel method for the synthesis of
CC   tetradecapeptides of the general formula
CC   H-Thr-Glu-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu-OH. The method
CC   involves condensation of a pentapeptide of the formula:
CC   Z-Thr(But)-Glu(But) Lys(Boc)-Lys(Boc)-Arg-OH with nonapeptide of the
CC   formula: Arg-Glu(But)-Thr(But)-VAl-Glu(But)-Arg-Glu(But)-Lys(Boc)-Glu
CC   (But)-OBut followed by removal of protective groups in the synthesized
CC   semiproduct and preparing the end product. The method of the invention
CC   has applications for protein chemistry and biochemistry. This sequence
CC   represents a peptide used to illustrate the method of the invention.
XX
SQ   Sequence   9 AA;

  Query Match             100.0%;  Score 25;  DB 23;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 7.8e+05;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 EREKE 5
           |||||
Db       5 EREKE 9


RESULT 5
AAB82031
ID   AAB82031 standard; peptide; 11 AA.
XX
AC   AAB82031;
XX
DT   13-JUN-2001  (first entry)
XX
DE   Human hepreceptor domain B binding peptide Rupe414.
XX
KW   Human; hepreceptor; cytostatic; anti-HIV; antibiotic;
KW   nootropic; immune response inducer; ezrin; infectious diseases; cancer;
KW   HIV-related dementia.
XX
OS   Homo sapiens.
XX
PN   GB2354241-A.
XX
PD   21-MAR-2001.
XX
PF   17-SEP-1999;   99GB-0021881.
XX
PR   17-SEP-1999;   99GB-0021881.
XX
PA   (HOLM/) HOLMS R D.
XX
PI   Holms RD;
XX
DR   WPI; 2001-293287/31.
XX
PT   Novel regulatory or unfolding peptides of ezrin that binds to
PT   Hepreceptor, useful for inducing immune response for treating
PT   infectious diseases and cancer  -
XX
PS   Claim 16; Page 36; 42pp; English.
XX
CC   The hepreceptor is a novel active site in human ezrin. Ezrin regulates
CC   the structure of the cortical cytoskeleton to control cell surface
CC   topography. The present invention relates to peptides (see AAB82021 to
CC   AAB82041) that bind to hepreceptor with greater affinity than HBP1 (see
CC   AAB82046). The hepreceptor binding peptides are useful for inducing
CC   immune response, and for treating infectious diseases, cancer and
CC   HIV-related dementia. The present peptide binds to domain B of the
CC   hepreceptor (AAB82020).
XX
SQ   Sequence   11 AA;

  Query Match             100.0%;  Score 25;  DB 22;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 44;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 EREKE 5
           |||||
Db       7 EREKE 11


RESULT 6
AAW26551
ID   AAW26551 standard; Peptide; 12 AA.
XX
AC   AAW26551;
XX
DT   16-JAN-1998  (first entry)
```

```
XX
DE   Epithelial protein (precancer marker) peptide.
XX
KW   Epithelial protein; heterogeneous nuclear ribonuclear protein;
KW   703D4 antigen; hnRNP-A2; hnRNP-B1; lung cancer; liver cancer;
KW   renal cancer; prostate cancer; melanoma; head cancer;
KW   neck cancer; myeloma; marker; carcinogenesis; diagnosis; human.
XX
OS   Homo sapiens.
XX
PN   WO9712975-A1.
XX
PD   10-APR-1997.
XX
PF   02-OCT-1996;   96WO-US15825.
XX
PR   02-OCT-1996;   96US-0725027.
PR   02-OCT-1995;   95US-0538711.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Mulshine JL,  Tockman MS;
XX
DR   WPI; 1997-226219/20.
XX
PT   A new purified protein from epithelial cells - is expressed in high
PT   amounts in cancer and precancer cells, used as a marker for
PT   diagnosis and treatment of cancer
XX
PS   Claim 2; Page 138; 171pp; English.
XX
CC   6 Claimed peptides (AAW26546-51) are CNBr fragments of an epithelial
CC   protein, the antigen for monoclonal antibody 703D4, whose increased
CC   presence in an epithelial cell is indicative of precancer,
CC   especially lung cancer.  The major epithelial protein was purified
CC   from human lung cancer lines NCI-H720 and NCI-H157.  It shares some
CC   sequence homology with the heterogeneous nuclear ribonucleoprotein
CC   (hnRNP) A2 (see AAW26553).  A minor copurifying epithelial protein
CC   shares some sequence homology with the splice variant hnRNP-B1 (see
CC   AAW26552).  The epithelial protein is a marker of epithelial
CC   transformation in lung, breast, bone, ovary, prostate, kidney,
CC   melanoma and myeloma, and may be causal in the process of
CC   carcinogenesis.  Methods are provided for monitoring the expression
CC   of the epithelial protein, peptides and variants using molecular
CC   and immunological techniques as a screen for (pre)cancer.  A method
CC   of computerised diagnosis of (pre)cancer is claimed that detects
CC   levels of hnRNP mRNA.  Also claimed are expression vectors, host
CC   cells and nucleic acid probes and primers useful in diagnostic
CC   screens for lung, renal, breast or prostate cancer, myeloma and
CC   melanoma.
XX
SQ   Sequence   12 AA;

  Query Match             100.0%;  Score 25;  DB 18;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 48;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 EREKE 5
           |||||
Db       1 EREKE 5


RESULT 7
AAW50920
ID   AAW50920 standard; peptide; 12 AA.
XX
AC   AAW50920;
XX
DT   09-SEP-1998  (first entry)
XX
DE   Amino acid sequence of a human epithelial peptide.
XX
KW   Human epithelial peptide; marker; cancer; probe; hybridisation;
KW   primer; amplification; lung; liver; kidney; breast; prostate;
KW   melanoma; myeloma; antibody.
XX
OS   Homo sapiens.
XX
PN   WO9814469-A2.
XX
PD   09-APR-1998.
XX
PF   02-OCT-1997;   97WO-US17714.
XX
PR   02-OCT-1996;   96US-0725027.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS.
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Mulshine JL,  Tockman MS;
XX
DR   WPI; 1998-240016/21.
XX
PT   New isolated epithelial protein as early marker of cancer - useful
PT   in computer-assisted methods of diagnosis based on discriminant
PT   analysis of optical images of cells
XX
PS   Claim 2; Page 10; 159; English.
XX
CC   This is the amino acid sequence of the human epithelial peptide, used
CC   in the method of the invention as early markers for cancer.  Probes
CC   and primers that hybridise to or amplify these peptides are used to
CC   diagnose precancerous states, e.g. of lung, liver, kidney, breast,
CC   prostate, head or neck, melanoma or myeloma, or to determine
CC   susceptibility to these conditions and for monitoring treatment.
CC   Precancer is also indicated by detecting post translational
CC   modification of the epithelial peptide which is a marker of epithelial
CC   cell transformation.  Antibodies are potentially useful for diagnosis
CC   and treatment of cancer.
XX
SQ   Sequence   12 AA;

  Query Match             100.0%;  Score 25;  DB 19;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 48;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 EREKE 5
           |||||
Db       1 EREKE 5


RESULT 8
AAB82028
ID   AAB82028 standard; peptide; 12 AA.
XX
AC   AAB82028;
XX
DT   13-JUN-2001  (first entry)
XX
DE   Human hepreceptor domain B binding peptide Rupe314.
XX
KW   Human; hepreceptor; cytostatic; anti HIV; antibiotic;
KW   nootropic; immune response inducer; ezrin; infectious diseases; cancer;
KW   HIV-related dementia.
XX
OS   Homo sapiens.
XX
PN   GB2354241-A.
XX
PD   21-MAR-2001.
XX
PF   17-SEP-1999;   99GB-0021881.
XX
PR   17-SEP-1999;   99GB-0021881.
XX
```

PA (HOLM/) HOLMS R D.
XX
PI Holms RD;
XX
DR WPI; 2001-293287/31.
XX
PT Novel regulatory or unfolding peptides of ezrin that binds to
PT Hepreceptor, useful for inducing immune response for treating
PT infectious diseases and cancer -
XX
PS Claim 13; Page 36; 42pp; English.
XX
CC The hepreceptor is a novel active site in human ezrin. Ezrin regulates
CC the structure of the cortical cytoskeleton to control cell surface
CC topography. The present invention relates to peptides (see AAB82021 to
CC AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see
CC AAB82046). The hepreceptor binding peptides are useful for inducing
CC immune response, and for treating infectious diseases, cancer and
CC HIV-related dementia. The present peptide binds to domain B of the
CC hepreceptor (AAB82020).
XX
SQ Sequence 12 AA;

Query Match 100.0%; Score 25; DB 22; Length 12;
Best Local Similarity 100.0%; Pred. No. 48;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EREKE 5
|||||
Db 8 EREKE 12

RESULT 9
AAR88086
ID AAR88086 standard; peptide; 14 AA.
XX
AC AAR88086;
XX
DT 13-JUL-1996 (first entry)
XX
DE Human endogenous peptide 1 (Ezrin residues 324-337).
XX
KW ezrin; P81; human endogenous peptide 1; human immunodeficiency virus;
KW HIV; conserved region; C4; carboxy-terminus; homology; treatment;
KW prophylaxis; AIDS; autoimmune deficiency syndrome;
KW systemic erythematosus lupus; SLE.
XX
OS Synthetic.
XX
PN GB2290293-A.
XX
PD 20-DEC-1995.
XX
PF 08-JUN-1994; 94GB-0011534
XX
PR 08-JUN-1994; 94GB-0011534
XX
PA (HOLM/) HOLMS R D.
XX
PI Holms RD;
XX
DR WPI; 1996-022440/03
XX
PT Peptide compsns. corresponding to HIV sequences used for the
PT prevention and treatment of AIDS, systemic lupus erythematosus or
PT related disorders.
XX
PS Claim 1; Page 24; 55pp; English.
XX
CC The present sequence designated human endogenous peptide 1 (HEP1) is
CC identical to amino acids 324 to 337 of human ezrin. Ezrin is a human
CC tubulin binding protein found in the cytoplasm of T cells and is
CC phosphorylated by tryosine kinase during T cell activation. Ezrin is
CC also known as P81. This peptide has a 70% sequence homology to VHP1
CC (a conserved C4 region at the C-terminus of human immunodeficiency virus
CC (HIV) gp120, residues 498 510). Compsns. contg. HEP1 or a mixt. of two
CC or more peptides or derivs. can be used for the prophylaxis and treatment
CC of AIDS, systemic lupus erythematosus and related disorders. HEP1
CC inhibits in vivo, in humans, HIV virus or autoimmune or autoreactive
CC responses.
XX
SQ Sequence 14 AA;

Query Match 100.0%; Score 25; DB 17; Length 14;
Best Local Similarity 100.0%; Pred. No. 56;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EREKE 5
|||||
Db 10 EREKE 14

RESULT 10
AAB82035
ID AAB82035 standard; peptide; 14 AA.
XX
AC AAB82035;
XX
DT 13-JUN-2001 (first entry)
XX
DE Human hepreceptor domain A/B binding peptide Rupe1024.
XX
KW Human, hepreceptor, cytostatic, anti-HIV, antibiotic;
KW nootropic; immune response inducer; ezrin; infectious diseases; cancer;
KW HIV-related dementia.
XX
OS Homo sapiens.
XX
PN GB2354241-A.
XX
PD 21-MAR-2001.
XX
PF 17-SEP-1999; 99GB-0021881.
XX
PR 17-SEP-1999; 99GB-0021881.
XX
PA (HOLM/) HOLMS R D.
XX
PI Holms RD;
XX
DR WPI; 2001-293287/31.
XX
PT Novel regulatory or unfolding peptides of ezrin that binds to
PT Hepreceptor, useful for inducing immune response for treating
PT infectious diseases and cancer -
XX
PS Claim 20; Page 36; 42pp; English.
XX
CC The hepreceptor is a novel active site in human ezrin. Ezrin regulates
CC the structure of the cortical cytoskeleton to control cell surface
CC topography. The present invention relates to peptides (see AAB82021 to
CC AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see
CC AAB82046) The hepreceptor binding peptides are useful for inducing
CC immune response, and for treating infectious diseases, cancer and
CC HIV related dementia. The present peptide binds to domains A and B of the
CC hepreceptor (AAB82019 and AAB82020).
XX
SQ Sequence 14 AA;

Query Match 100.0%; Score 25; DB 22; Length 14;
Best Local Similarity 100.0%; Pred. No. 56;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EREKE 5
|||||
Db 1 EREKE 5

```
RESULT 11
AAB82046
ID   AAB82046 standard; peptide; 14 AA.
XX
AC   AAB82046;
XX
DT   13-JUN-2001  (first entry)
XX
DE   Human hepreceptor peptide Hep1.
XX
KW   Human; hepreceptor; cytostatic; anti-HIV; antibiotic; Hep1;
KW   nootropic; immune response inducer; ezrin; infectious diseases; cancer;
KW   HIV-related dementia.
XX
OS   Homo Sapiens.
XX
PN   GB2354241-A.
XX
PD   21-MAR-2001.
XX
PF   17-SEP-1999;   99GB-0021881.
XX
PR   17-SEP-1999;   99GB-0021881.
XX
PA   (HOLM/) HOLMS R D.
XX
PI   Holms RD;
XX
DR   WPI; 2001-293287/31
XX
PT   Novel regulatory or unfolding peptides of ezrin that binds to
PT   Hepreceptor, useful for inducing immune response for treating
PT   infectious diseases and cancer -
XX
PS   Example 4; Page 24; 42pp; English.
XX
CC   The hepreceptor is a novel active site in human ezrin. Ezrin regulates
CC   the structure of the cortical cytoskeleton to control cell surface
CC   topography. The present invention relates to peptides (see AAB82021 to
CC   AAB82041) that bind to hepreceptor with greater affinity than HEP1 (the
CC   present peptide). The hepreceptor binding peptides are useful for
CC   inducing immune response, and for treating infectious diseases, cancer
CC   and HIV related dementia.
XX
SQ   Sequence   14 AA;

  Query Match           100.0%;  Score 25;  DB 22;  Length 14;
  Best Local Similarity  100.0%;  Pred. No. 56;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 EREKE 5
             |||||
Db      10 EREKE 14


RESULT 12
AAM49722
ID   AAM49722 standard; peptide; 14 AA.
XX
AC   AAM49722;
XX
DT   14-JUN-2002  (first entry)
XX
DE   HEP-1 associated peptide.
XX
KW   Tetradecapeptide synthesis; condensation; protein chemistry;
KW   biochemistry.
XX
OS   Unidentified.
XX
PN   RU2175973-C1.
XX
PD   20-NOV-2001.
XX
PF   10-AUG-2000;  2000RU-0120792.
XX
PR   10-AUG-2000;  2000RU-0120792.
XX
PA   (GEPV-) GEPVITANIYA LTD.
XX
PI   Pomogaibo SV,  Buryakova AA;
XX
DR   WPI; 2002-081347/11.
XX
PT   Method of synthesis of tetradecapeptide -
XX
PS   Claim 1; Column 3; 6pp; Russian.
XX
CC   This invention describes a novel method for the synthesis of
CC   tetradecapeptides of the general formula
CC   H-Thr-Glu-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu-OH. The method
CC   involves condensation of a pentapeptide of the formula:
CC   Z-Thr(But)-Glu(But)-Lys(Boc)-Lys(Boc)-Arg-OH with nonapeptide of the
CC   formula: Arg-Glu(But)-Thr(But)-VAl-Glu(But)-Arg-Glu(But)-Lys(Boc)-Glu
CC   (But)-OBut followed by removal of protective groups in the synthesized
CC   semiproduct and preparing the end product. The method of the invention
CC   has applications for protein chemistry and biochemistry. This sequence
CC   represents a peptide used to illustrate the method of the invention.
XX
SQ   Sequence   14 AA;

  Query Match           100.0%;  Score 25;  DB 23;  Length 14;
  Best Local Similarity  100.0%;  Pred. No. 56;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 EREKE 5
             |||||
Db      10 EREKE 14


RESULT 13
AAB82019
ID   AAB82019 standard; peptide; 32 AA.
XX
AC   AAB82019;
XX
DT   13-JUN-2001  (first entry)
XX
DE   Human hepreceptor domain A.
XX
KW   Human; hepreceptor domain A; cytostatic; anti-HIV; antibiotic;
KW   nootropic; immune response inducer; ezrin; infectious diseases; cancer;
KW   HIV-related dementia.
XX
OS   Homo sapiens.
XX
PN   GB2354241-A.
XX
PD   21-MAR-2001.
XX
PF   17-SEP-1999;   99GB-0021881.
XX
PR   17-SEP-1999;   99GB-0021881.
XX
PA   (HOLM/) HOLMS R D.
XX
PI   Holms RD;
XX
DR   WPI; 2001-293287/31.
XX
PT   Novel regulatory or unfolding peptides of ezrin that binds to
PT   Hepreceptor, useful for inducing immune response for treating
PT   infectious diseases and cancer -
XX
```

PS Claim 4; Page 36; 42pp; English.
XX
CC The present sequence is domain A of human hepreceptor of human ezrin. The
CC hepreceptor is a novel active site in human ezrin. Ezrin regulates the
CC structure of the cortical cytoskeleton to control cell surface
CC topography. The present invention relates to peptides (see AAB82021 to
CC AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see
CC AAB82046) The hepreceptor binding peptides are useful for inducing
CC immune response, and for treating infectious diseases, cancer and
CC HIV-related dementia. The present sequence assembles into two
CC anti-parallel helices with hepreceptor domain B (see AAB82020).
XX
SQ Sequence 32 AA;

Query Match 100.0%; Score 25; DB 22; Length 32;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EREKE 5
||||| |
Db 26 EREKE 30

RESULT 14
AAO08880
ID AAO08880 standard; Protein; 34 AA.
XX
AC AAO08880;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 22772.
XX
KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW tissue growth factor; immunomodulatory; cancer; leukaemia;
KW nervous system disorders; arthritis; inflammation
XX
OS Homo sapiens.
XX
PN WO200164835-A2
XX
PD 07-SEP-2001
XX
PF 26-FEB-2001; 2001WO-US04927.
XX
PR 28-FEB-2000; 2000US-0515126
PR 18-MAY-2000; 2000US-0577409.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Drmanac RT;
XX
DR WPI; 2001-514838/56.
DR N-PSDB; AAI88811.
XX
PT Isolated nucleic acids and polypeptides, useful for preventing
PT diagnosing and treating e.g. leukaemia, inflammation and immune
PT disorders -
XX
PS Claim 20; SEQ ID NO 22772; 1399pp - Sequence Listing; English.
XX
CC The invention relates to human polynucleotides (AAI79941-AAI93841) and
CC the encoded proteins (AAO00010-AAO13910) that exhibit activity relating to
CC cytokine, cell proliferation or cell differentiation of which may induce
CC production of other cytokines in other cell populations. The
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC peptide therapy. The polypeptides have various cytokine-like activities,
CC e.g. stem cell growth factor activity, haematopoiesis regulating
CC activity, tissue growth factor activity, immunomodulatory activity and
CC activin/inhibin activity and may be useful in the diagnosis and/or
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC inflammation.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 34 AA;

Query Match 100.0%; Score 25; DB 22; Length 34;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EREKE 5
||||| |
Db 20 EREKE 24

RESULT 15
ABB30745
ID ABB30745 standard; Peptide; 39 AA.
XX
AC ABB30745;
XX
DT 01-FEB-2002 (first entry)
XX
DE Peptide #3396 encoded by breast cell single exon nucleic acid probe.
XX
KW Human; microarray; single exon probe; gene expression; breast;
KW disease; cancer.
XX
OS Homo sapiens.
XX
PN WO200157271-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US03052.
XX
PR 04-FEB-2000; 2000US-0180312
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408
PR 03-AUG-2000; 2000US-0632466.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hansel DE, Chen W, Park DF;
XX
DR WPI; 2001-496933/54.
XX
PT New spatially-addressable set of single exon nucleic acid probes,
PT useful for measuring gene expression in sample derived from human
PT breast, comprises number of single exon nucleic acid probes -
XX
PS Claim 27; SEQ ID NO 13713; 327pp + sequence listing; English.
XX
CC The invention relates to a spatially addressable set of single exon
CC nucleic acid probes for measuring gene expression in a sample derived
CC from human breast and BI 474 cells. The method involves contacting
CC the probes with a collection of detectably labelled nucleic acids
CC derived from mRNA of human breast, and then measuring the label
CC bound to each probe of the microarray. The probes are useful for
CC verifying the expression of regions of genomic DNA predicted to
CC encode proteins. They are useful for gene discovery, and for
CC determining predisposition and/or prognosing breast disease. Gene
CC expression analysis is useful for assessing the toxicity of chemical
CC agents on cells. The microarray of this invention presents a far greater
CC diversity of probes for measuring gene expression, with far less bias
CC than expressed sequence tag microarrays. The method is suitable for
CC rapid production of functional information from genomic sequence. The
CC present sequence is a peptide encoded by a single exon nucleic acid
CC probe of the invention.
CC Note: The sequence data for this patent did not form part of the

CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 49 AA;

Query Match 100.0%; Score 25; DB 22; Length 39;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EKEKE 5
||||| |
Db 28 EKEKE 32

Search completed: January 16, 2003, 16:49:11
Job time : 24.7857 secs